deferoxamine has been researched along with Mucorales Infection in 42 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study investigates the pathophysiology of mucormycosis caused by Rhizopus, which has been reported in 46 dialysis patients, while treated with deferoxamine (DFO)." | 7.68 | Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. ( Boelaert, JR; Cantinieaux, B; de Locht, M; Kerrels, V; Schneider, YJ; Van Cutsem, J; Van Landuyt, HW; Verdonck, A, 1993) |
| "Two maintenance hemodialysis patients receiving deferoxamine to chelate iron and aluminum developed intestinal mucormycosis." | 7.67 | Intestinal mucormycosis in hemodialysis patients following deferoxamine. ( Eiser, AR; Neff, MS; Slifkin, RF, 1987) |
| "Mucormycosis was induced in healthy guinea pigs by the i." | 5.28 | Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis). ( Boelaert, JR; Van Cutsem, J, 1989) |
| "Deferoxamine (DFO) has been widely used in the treatment of aluminum toxicity in patients on chronic dialysis." | 5.28 | [A case report of rhinocerebral mucormycosis in hemodialysis patient receiving deferoxamine]. ( Arizono, K; Fukui, H; Hayano, K; Miura, H; Otsuka, Y; Tajiri, M, 1989) |
| "The increased risk of mucormycosis in patients with renal failure receiving deferoxamine iron chelation therapy is explained by the fact that deferoxamine actually acts as a siderophore for the agents of mucormycosis, supplying previously unavailable iron to the fungi." | 4.84 | Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. ( Edwards, J; Ibrahim, AS; Spellberg, B, 2008) |
| " In July 1996, deferoxamine was administered for iron overload." | 4.80 | [Development of arterial thrombus of Mucorales hyphae during deferoxamine therapy in a patient with aplastic anemia in transformation to myelodysplastic syndrome]. ( Kajiguchi, T; Miyata, Y; Saito, M; Takeyama, H, 2000) |
| "A case of fatal intestinal mucormycosis in a 57-year-old female hemodialysis patient who had received desferrioxamine (DFO) for aluminum overload is reported." | 4.78 | Intestinal mucormycosis in a hemodialysis patient treated with desferrioxamine. ( Abe, F; Hotchi, M; Ito, M; Kaneko, T; Okada, Y; Yamada, K, 1991) |
| "Dialysis patients with chronic renal failure receiving deferoxamine for treating iron overload are uniquely predisposed for mucormycosis, which is most often caused by Rhizopus oryzae." | 3.81 | Fob1 and Fob2 Proteins Are Virulence Determinants of Rhizopus oryzae via Facilitating Iron Uptake from Ferrioxamine. ( Chou, TF; Edwards, JE; French, SW; Gebremariam, T; Ibrahim, AS; Lin, L; Liu, M; Luo, G; Skory, CD, 2015) |
| "Deferoxamine (DFO), when used in dialysis patients, is a well recognized risk factor for the development of mucormycosis caused by Rhizopus." | 3.69 | Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. ( Boelaert, JR; Crichton, RR; de Locht, M; Schneider, YJ; Van Cutsem, J, 1994) |
| "This study investigates the pathophysiology of mucormycosis caused by Rhizopus, which has been reported in 46 dialysis patients, while treated with deferoxamine (DFO)." | 3.68 | Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. ( Boelaert, JR; Cantinieaux, B; de Locht, M; Kerrels, V; Schneider, YJ; Van Cutsem, J; Van Landuyt, HW; Verdonck, A, 1993) |
| "Two maintenance hemodialysis patients receiving deferoxamine to chelate iron and aluminum developed intestinal mucormycosis." | 3.67 | Intestinal mucormycosis in hemodialysis patients following deferoxamine. ( Eiser, AR; Neff, MS; Slifkin, RF, 1987) |
| " The interdialytic half-life of ferrioxamine was 2." | 2.67 | Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients. ( Becaus, I; Boelaert, JR; D'Haese, PC; De Broe, ME; Lamberts, LV; Verpooten, GA, 1992) |
| "Mucormycosis was the primary cause of death in three of the five patients." | 1.30 | Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. ( Boogaerts, MA; Demuynck, H; Maertens, J; Vandenberghe, P; Verbeken, EK; Verhoef, GE; Zachée, P, 1999) |
| "Mucormycosis was induced in healthy guinea pigs by the i." | 1.28 | Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis). ( Boelaert, JR; Van Cutsem, J, 1989) |
| "Deferoxamine (DFO) has been widely used in the treatment of aluminum toxicity in patients on chronic dialysis." | 1.28 | [A case report of rhinocerebral mucormycosis in hemodialysis patient receiving deferoxamine]. ( Arizono, K; Fukui, H; Hayano, K; Miura, H; Otsuka, Y; Tajiri, M, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (35.71) | 18.7374 |
| 1990's | 19 (45.24) | 18.2507 |
| 2000's | 7 (16.67) | 29.6817 |
| 2010's | 1 (2.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, M | 1 |
| Lin, L | 1 |
| Gebremariam, T | 1 |
| Luo, G | 1 |
| Skory, CD | 1 |
| French, SW | 1 |
| Chou, TF | 1 |
| Edwards, JE | 1 |
| Ibrahim, AS | 2 |
| Spellberg, B | 1 |
| Edwards, J | 1 |
| Kubota, N | 2 |
| Miyazawa, K | 2 |
| Shoji, N | 2 |
| Sumi, M | 2 |
| Nakajima, A | 2 |
| Kimura, Y | 2 |
| Oshiro, H | 2 |
| Ebihara, Y | 2 |
| Ohyashiki, K | 2 |
| Wu, VC | 1 |
| Wang, R | 1 |
| Lai, TS | 1 |
| Wu, KD | 1 |
| Keijzer, A | 1 |
| van der Valk, P | 1 |
| Ossenkoppele, GJ | 1 |
| van de Loosdrecht, AA | 1 |
| Boelaert, JR | 11 |
| Van Cutsem, J | 3 |
| de Locht, M | 4 |
| Schneider, YJ | 4 |
| Crichton, RR | 1 |
| Olivero, JJ | 1 |
| Kerrels, V | 1 |
| Cantinieaux, B | 1 |
| Verdonck, A | 1 |
| Van Landuyt, HW | 1 |
| Maertens, J | 1 |
| Demuynck, H | 1 |
| Verbeken, EK | 1 |
| Zachée, P | 1 |
| Verhoef, GE | 1 |
| Vandenberghe, P | 1 |
| Boogaerts, MA | 1 |
| Miyata, Y | 1 |
| Kajiguchi, T | 1 |
| Saito, M | 1 |
| Takeyama, H | 1 |
| Barratt, DM | 1 |
| Van Meter, K | 1 |
| Asmar, P | 1 |
| Nolan, T | 1 |
| Trahan, C | 1 |
| Garcia-Covarrubias, L | 1 |
| Metzinger, SE | 1 |
| Verpooten, GA | 1 |
| D'Haese, PC | 1 |
| Becaus, I | 1 |
| Lamberts, LV | 1 |
| De Broe, ME | 1 |
| Seeverens, HJ | 1 |
| Tijhuis, GJ | 1 |
| Ruijs, GJ | 1 |
| Kazzaz, BA | 1 |
| Kauffmann, RH | 1 |
| Ammon, A | 1 |
| Rumpf, KW | 1 |
| Hommerich, CP | 1 |
| Behrens-Baumann, W | 1 |
| Rüchel, R | 1 |
| Anand, VK | 1 |
| Alemar, G | 1 |
| Griswold, JA | 1 |
| Wens, R | 1 |
| Devriendt, J | 1 |
| Collart, F | 1 |
| Dratwa, M | 1 |
| Bisschop, P | 1 |
| Telerman-Toppet, N | 1 |
| Douat, N | 1 |
| Kaneko, T | 1 |
| Abe, F | 2 |
| Ito, M | 1 |
| Hotchi, M | 2 |
| Yamada, K | 1 |
| Okada, Y | 1 |
| Slade, MP | 1 |
| McNab, AA | 1 |
| Fenves, AZ | 3 |
| Coburn, JW | 2 |
| Ponz, E | 1 |
| Campistol, JM | 1 |
| Ribalta, T | 1 |
| Montoliú, J | 1 |
| Ramírez, J | 1 |
| Almirall, J | 1 |
| Revert, L | 1 |
| Vlasveld, LT | 1 |
| van Asbeck, BS | 1 |
| Vandevelde, L | 1 |
| Bondewel, C | 1 |
| Dubois, M | 1 |
| De Vuyst, M | 1 |
| Inaba, H | 1 |
| Katoh, T | 1 |
| Hamdy, NA | 1 |
| Andrew, SM | 1 |
| Shortland, JR | 1 |
| Boletis, J | 1 |
| Raftery, AT | 1 |
| Kanis, JA | 1 |
| Brown, CB | 1 |
| Daly, AL | 1 |
| Velazquez, LA | 1 |
| Bradley, SF | 1 |
| Kauffman, CA | 1 |
| Nakamura, M | 1 |
| Weil, WB | 1 |
| Kaufman, DB | 1 |
| Arizono, K | 1 |
| Fukui, H | 1 |
| Miura, H | 1 |
| Hayano, K | 1 |
| Otsuka, Y | 1 |
| Tajiri, M | 1 |
| Sane, A | 1 |
| Manzi, S | 1 |
| Perfect, J | 1 |
| Herzberg, AJ | 1 |
| Moore, JO | 1 |
| van Roost, GF | 1 |
| Vergauwe, PL | 2 |
| Verbanck, JJ | 1 |
| de Vroey, C | 1 |
| Segaert, MF | 1 |
| Fenves, A | 1 |
| Windus, D | 1 |
| Goodill, JJ | 1 |
| Abuelo, JG | 1 |
| Eiser, AR | 1 |
| Slifkin, RF | 1 |
| Neff, MS | 1 |
| Scheer, RL | 1 |
| Veis, JH | 1 |
| Contiguglia, R | 1 |
| Klein, M | 1 |
| Mishell, J | 1 |
| Alfrey, AC | 1 |
| Shapiro, JI | 1 |
| Windus, DW | 1 |
| Stokes, TJ | 1 |
| Julian, BA | 1 |
| Vandepitte, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia[NCT01822015] | Early Phase 1 | 55 participants (Actual) | Interventional | 2013-03-15 | Completed | ||
| The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study[NCT00419770] | Phase 2 | 20 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00419770)
Timeframe: 30 Days After End of Therapy
| Intervention | Events (Number) |
|---|---|
| Deferasirox | 16 |
| Placebo | 16 |
10 reviews available for deferoxamine and Mucorales Infection
| Article | Year |
|---|---|
Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment.
Topics: Animals; Benzoates; Chelating Agents; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Microbia | 2008 |
Mucormycosis (zygomycosis): is there news for the clinician?
Topics: AIDS-Related Opportunistic Infections; Deferoxamine; Disease Susceptibility; Drug Therapy; Humans; M | 1994 |
[Development of arterial thrombus of Mucorales hyphae during deferoxamine therapy in a patient with aplastic anemia in transformation to myelodysplastic syndrome].
Topics: Anemia, Aplastic; Chelating Agents; Deferoxamine; Fatal Outcome; Female; Humans; Iron Overload; Midd | 2000 |
Dialysis associated mucormycosis and desferrioxamine treatment: a case report with review of the role of oxygen radicals.
Topics: Adult; Deferoxamine; Free Radicals; Humans; Male; Mucormycosis; Reactive Oxygen Species; Renal Dialy | 1992 |
Intracranial complications of mucormycosis: an experimental model and clinical review.
Topics: Adult; Alloxan; Amphotericin B; Animals; Brain Abscess; Brain Diseases; Child; Deferoxamine; Diabete | 1992 |
Intestinal mucormycosis in a hemodialysis patient treated with desferrioxamine.
Topics: Aluminum; Deferoxamine; Female; Humans; Intestinal Diseases; Middle Aged; Mucormycosis; Renal Dialys | 1991 |
Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry.
Topics: Adolescent; Adult; Aged; Deferoxamine; Female; Humans; Male; Middle Aged; Mucormycosis; Registries; | 1991 |
[Disseminated mucormycosis in a hemodialyzed female patient treated with deferoxamine].
Topics: Deferoxamine; Female; Humans; Kidney Failure, Chronic; Middle Aged; Mucormycosis; Renal Dialysis | 1991 |
Mucormycosis: association with deferoxamine therapy.
Topics: Deferoxamine; Drug Overdose; Female; Humans; Iron; Middle Aged; Mucormycosis; Myelodysplastic Syndro | 1989 |
The role of desferrioxamine in dialysis-associated mucormycosis: report of three cases and review of the literature.
Topics: Adult; Deferoxamine; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Mucormycosis; Renal | 1988 |
1 trial available for deferoxamine and Mucorales Infection
| Article | Year |
|---|---|
Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients.
Topics: Adult; Aged; Aluminum; Chelating Agents; Deferoxamine; Ferric Compounds; Hemosiderosis; Humans; Live | 1992 |
31 other studies available for deferoxamine and Mucorales Infection
| Article | Year |
|---|---|
Fob1 and Fob2 Proteins Are Virulence Determinants of Rhizopus oryzae via Facilitating Iron Uptake from Ferrioxamine.
Topics: Animals; Biological Transport; Deferoxamine; DNA-Binding Proteins; Ferric Compounds; Iron; Iron Chel | 2015 |
A massive intraventricular thrombosis by disseminated mucormycosis in a patient with myelodysplastic syndrome during deferoxamine therapy.
Topics: Aged; Cerebral Ventricle Neoplasms; Cerebral Ventricles; Deferoxamine; Fatal Outcome; Humans; Male; | 2003 |
A massive intraventricular thrombosis by disseminated mucormycosis in a patient with myelodysplastic syndrome during deferoxamine therapy.
Topics: Aged; Anemia, Refractory; Deferoxamine; Echocardiography; Fatal Outcome; Heart Diseases; Heart Ventr | 2003 |
Deferoxamine-related fatal nasal-orbital-cerebral mucormycosis.
Topics: Deferoxamine; Facial Bones; Fatal Outcome; Female; Humans; Middle Aged; Mucormycosis; Siderophores | 2006 |
Mucormycosis in a patient with low risk myelodysplasia treated with anti-TNF-alpha.
Topics: Anemia, Refractory; Anemia, Sideroblastic; Antibodies, Monoclonal; Apoptosis; Combined Modality Ther | 2006 |
Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect.
Topics: Animals; Deferiprone; Deferoxamine; Guinea Pigs; Iron; Iron Chelating Agents; Male; Mucormycosis; Py | 1994 |
Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus.
Topics: 2,2'-Dipyridyl; Albumins; Cells, Cultured; Deferoxamine; Ferric Compounds; Humans; Iron; Mucormycosi | 1994 |
The effect of deferoxamine on different zygomycetes.
Topics: Deferoxamine; Iron; Mucorales; Mucormycosis; Rhizopus | 1994 |
Hemoptysis and altered sensorium in a hemodialysis patient.
Topics: Aluminum; Aluminum Hydroxide; Brain Diseases; Deferoxamine; Hemoptysis; Humans; Kidney Failure, Chro | 1993 |
Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies.
Topics: Animals; Blood Physiological Phenomena; Candida albicans; Candidiasis; Deferoxamine; Guinea Pigs; Hu | 1993 |
Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis.
Topics: Adult; Bone Marrow Transplantation; Deferoxamine; Female; Humans; Iron Overload; Male; Middle Aged; | 1999 |
Hyperbaric oxygen as an adjunct in zygomycosis: randomized controlled trial in a murine model.
Topics: Amphotericin B; Animals; Antifungal Agents; Combined Modality Therapy; Deferoxamine; Female; Hyperba | 2001 |
[Rhinocerebral mucormycosis during deferoxamine therapy].
Topics: Adult; Blindness; Brain Diseases; Cellulitis; Combined Modality Therapy; Deferoxamine; Female; Human | 1992 |
Rhinocerebral mucormycosis in haemodialysis patients treated with desferrioxamine: possible role of recent surgery as an additional risk factor.
Topics: Amphotericin B; Brain Diseases; Deferoxamine; Humans; Male; Middle Aged; Mucormycosis; Nasal Mucosa; | 1991 |
Fatal mucormycosis therapy associated with deferoxamine.
Topics: Aged; Cellulitis; Deferoxamine; Humans; Male; Mucormycosis; Orbital Diseases | 1991 |
Treatment with deferoxamine: a real risk factor for mucormycosis?
Topics: Aluminum; Deferoxamine; Dialysis; Humans; Injections, Intramuscular; Iron; Male; Middle Aged; Mucorm | 1991 |
Mucorales and deferoxamine: from saprophytic to pathogenic state.
Topics: Deferoxamine; Ethmoid Sinusitis; Humans; Intracranial Embolism and Thrombosis; Male; Middle Aged; Mu | 1990 |
Effects of iron and desferrioxamine on Rhizopus infection.
Topics: Animals; Brain; Deferoxamine; Drug Interactions; Iron; Kidney; Male; Mice; Mice, Inbred ICR; Mucormy | 1990 |
Fatal cardiac zygomycosis in a renal transplant patient treated with desferrioxamine.
Topics: Adult; Deferoxamine; Endomyocardial Fibrosis; Heart Ventricles; Humans; Immunosuppressive Agents; Ki | 1989 |
Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis).
Topics: Amphotericin B; Animals; Deferoxamine; Ferric Compounds; Guinea Pigs; Iron; Iron Chelating Agents; M | 1989 |
Fatal fungal peritonitis in an adolescent on continuous ambulatory peritoneal dialysis: association with deferoxamine.
Topics: Adolescent; Deferoxamine; Glomerulonephritis, Membranous; Humans; Kidney Failure, Chronic; Male; Muc | 1989 |
[A case report of rhinocerebral mucormycosis in hemodialysis patient receiving deferoxamine].
Topics: Brain Diseases; Deferoxamine; Humans; Kidney Failure, Chronic; Male; Middle Aged; Mucormycosis; Rena | 1989 |
Mucormycosis among patients on dialysis.
Topics: Deferoxamine; Humans; Mucormycosis; Renal Dialysis | 1989 |
Deferoxamine treatment as a risk factor for zygomycete infection.
Topics: Aged; Deferoxamine; Humans; Male; Mucormycosis; Opportunistic Infections; Rhizopus; Risk Factors | 1989 |
Uncertainty in clinical decisions.
Topics: Deferoxamine; Humans; Male; Middle Aged; Mucormycosis; Opportunistic Infections | 1988 |
Mucormycosis--a new risk of deferoxamine therapy in dialysis patients with aluminum or iron overload?
Topics: Adult; Aluminum; Deferoxamine; Humans; Iron; Male; Mucormycosis; Renal Dialysis | 1987 |
Intestinal mucormycosis in hemodialysis patients following deferoxamine.
Topics: Deferoxamine; Humans; Intestinal Diseases; Lung Diseases, Fungal; Male; Middle Aged; Mucormycosis; R | 1987 |
Myocardial mucormycosis with emboli in a hemodialysis patient.
Topics: Cardiomyopathies; Deferoxamine; Humans; Mucormycosis; Renal Dialysis | 1987 |
Mucormycosis in deferoxamine-treated patients on dialysis.
Topics: Deferoxamine; Humans; Mucormycosis; Renal Dialysis; Uremia | 1987 |
Fatal Rhizopus infections in hemodialysis patients receiving deferoxamine.
Topics: Adult; Aged; Aluminum; Deferoxamine; Encephalitis; Female; Hemosiderosis; Humans; Male; Middle Aged; | 1987 |
Mucormycosis infection in dialysis patients.
Topics: Deferoxamine; Humans; Iron; Mucormycosis; Renal Dialysis; Yersinia Infections | 1987 |